Competitor Landscape: Systemic Sclerosis (Scleroderma)
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Scope
The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher – these are outlined in the report Appendix
Forecasts are presented in pipeline forecast figures & detailed tables
‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided
Key Highlights
New Phase I study to evaluate drug-drug interactions could allow nintedanib to be administered concomitantly with relevant birth-control pills, potentially increasing the eligible patient population for nintedanib
Corbus Pharmaceuticals continues to present data for lenabasum at rheumatology conferences, as the company attempts to increase awareness of its late stage pipeline candidate, which could facilitate patient recruitment to its ongoing Phase III RESOLVE-1 trial
Completion of recruitment for SAR-156597's Phase II trial was confirmed ahead of its expected primary completion in Q4 2018
Reasons to Buy
Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
Reviews ongoing lifecycle management strategies for existing players in the market
A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts
Active Biotech
arGentis Pharmaceuticals
Assistance Publique - Hôpitaux de Paris
AstraZeneca
Bayer
Biogen
BMS
Boehringer Ingelheim
Celgene
Corbus Pharmaceuticals
CSL Behring
Cumberland Pharmaceuticals
Cytori
Daval International
Digna Biotech
EMD Serono & Merck KGaA
Emerald Health Pharmaceuticals
Fibrocell Science; Intrexon Corporation
Fred Hutchinson Cancer Research Center
Genentech (collaborator)
Gilead
GSK
Human Stem Cells Institute
iBio
Inventiva Pharma
Kadmon
miRagen
Novartis
Pfizer
Regeneron
Boston University
Roche
Samumed
Sanofi
Seattle Genetics
United Therapeutics
University of Pittsburgh
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.